Last reviewed · How we verify
Extended Meropenem
At a glance
| Generic name | Extended Meropenem |
|---|---|
| Also known as | Extended Infusion of Meropenem, Kener, Merrem, AstraZeneca |
| Sponsor | Coordinación de Investigación en Salud, Mexico |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections (PHASE3)
- EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS (PHASE4)
- PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN) (PHASE4)
- Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii (PHASE4)
- PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections (PHASE4)
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (PHASE4)
- Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended Meropenem CI brief — competitive landscape report
- Extended Meropenem updates RSS · CI watch RSS
- Coordinación de Investigación en Salud, Mexico portfolio CI